Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12596867 | 0.87 | KDM4E (0.45) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL25547290 | 0.83 | KDM4E (0.43) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL18624686 | 0.79 | KDM4E (0.38) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL14234928 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL27518825 | 0.79 | KDM4E (0.57) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL3558751 | 0.77 | ALDH1A1 (0.58) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL10908641 | 0.76 | MTNR1A (0.40) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL22300358 | 0.75 | KDM4E (0.53) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL3558749 | 0.75 | KDM4E (0.56) | KDM4EALDH1A1HPGDLMNACYP19A1 | |
| SCHEMBL15850980 | 0.74 | AXL (0.39) | KDM4EALDH1A1HPGDLMNACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2836494-B1 | NEW ALKYLATING AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-08-21 | — | — | EP | disclosed |
| EP-3049420-B1 | THIENO[2,3-E]INDOLE DERIVATIVES AS NEW ANTITUMOR AGENTS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2019-05-15 | — | — | EP | disclosed |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-04-23 | — | — | US | disclosed |
| US-20170071907-A1 | THIENO-INDOLE MOIETIES AND METHODS OF TREATING USING THE SAME | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-03-16 | — | — | US | disclosed |
| WO-2012162731-A1 | BLOOD STAGE MALARIA VACCINE | GRIFFITH UNIVERSITY (AU) | 2012-12-06 | — | — | WO | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| US-7718688-B2 | Nitrobenzindoles and their use in cancer therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-05-18 | — | — | US | disclosed |
| WO-2009064913-A1 | CHIMER CONTAINING A TARGETING PORTION LINKED TO A SCISSION-ACTIVATED DUOCARMYCIN-TYPE PRODRUG | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-05-22 | — | — | WO | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | AUCKLAND UNISERVICES LIMITED (NZ) | 2008-05-22 | — | — | US | disclosed |
| WO-2008050140-A2 | COMPOUNDS FOR TREATMENT OF PARASITIC INFECTION | SPIROGEN LIMITED (GB) | 2008-05-02 | — | — | WO | disclosed |
| US-7235578-B2 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-06-26 | — | — | US | disclosed |
| US-7235578-B2 | Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3H-[ring fused indol-5-yl-(amine-derived)] compounds and analogues thereof, and to products obtained therefrom | AUCKLAND UNISERVICES LIMITED (NZ) | 2007-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119442-A1 | as hypoxia-selective drugs and radiosensitizers for cancer therapy; nitroreductase inhibitor; 1-(Chloromethyl)-5,6-dinitro-3-(5,6,7-trimethoxyindol-2-carbonyl)-1,2-dihydro-3H-benzo[e]indole; halogenation of naphthalene derivative followed by hydration and cyclization | HIF1AN, HYOU1, HIF1A | KDM4E 856/4885ALDH1A1 77/4885HPGD 16/4885 |
| US-20170071907-A1 | THIENO-INDOLE MOIETIES AND METHODS OF TREATING USING THE SAME | INMT, TYMP, TOP1 | KDM4E 548/4885ALDH1A1 983/4885HPGD 1478/4885 |
| US-10266547-B2 | Thieno[2,3-e]indole derivatives as new antitumor agents | INMT, TOP2A, TOP1 | KDM4E 371/4885ALDH1A1 1221/4885HPGD 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.